Department of Oncology & Department of Breast Surgery, the Second Hospital of Dalian Medical University, 467#, Zhongshan Road, Shahekou distinct, Dalian, Liaoning Province 116023, China; Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing 100191, China.
Department of Oncology & Department of Breast Surgery, the Second Hospital of Dalian Medical University, 467#, Zhongshan Road, Shahekou distinct, Dalian, Liaoning Province 116023, China.
Life Sci. 2024 Feb 1;338:122389. doi: 10.1016/j.lfs.2023.122389. Epub 2023 Dec 29.
Cancer remains a significant global public health issue. There is growing proof that Ring Finger Protein 186 (RNF186) may play a function in pan-cancer, however, this has not yet been thoroughly determined. This study aims to analyze RNF186 with potential implications in progression and prognosis in human cancer.
A comprehensive bioinformatics approaches combined with experimental verification were used across 33 types of cancers in this study to conduct a pan-cancer investigation of RNF186 from the perspectives of gene expression, prognosis, genomic alterations, immunological markers, gene set, and function.
RNF186 is a valuable prognostic biomarker in several cancer types, especially breast invasive carcinoma (BRCA) and uterine corpus endometrial carcinoma (UCEC). The levels of RNF186 promoter methylation and genetic alterations may be responsible for some cancers' abnormal expression. Furthermore, RNF186 expression was determined to be associated with immune checkpoint genes. Analysis of RNF186-related genes revealed that proteasome and PI3K-AKT signaling pathway were primarily involved in the cellular function of RNF186. Additionally, our research first confirmed that RNF186 may function as an oncogene and contribute to cancer proliferation, migration and invasion in UCEC. In contrast, RNF186 may play an inhibitory role in BRCA progression. This function depends on the ligase activity of RNF186.
This study suggests that RNF186 is a novel critical target for tumor progression in BRCA and UCEC. It reveals that RNF186 may be associated with tumor immunotherapy, which may provide an effective predictive evaluation of the prognosis of immunotherapy.
癌症仍然是一个重大的全球公共卫生问题。越来越多的证据表明，环指蛋白 186（RNF186）可能在泛癌中发挥作用，但这尚未得到彻底确定。本研究旨在分析 RNF186 在人类癌症中的进展和预后中的潜在作用。
本研究综合应用了多种生物信息学方法，并结合实验验证，对 33 种癌症进行了泛癌研究，从基因表达、预后、基因组改变、免疫标志物、基因集和功能等方面对 RNF186 进行了研究。
RNF186 是几种癌症的有价值的预后生物标志物，特别是乳腺癌浸润性癌（BRCA）和子宫内膜癌（UCEC）。RNF186 启动子甲基化和遗传改变的水平可能导致某些癌症的异常表达。此外，RNF186 的表达与免疫检查点基因有关。对 RNF186 相关基因的分析表明，蛋白酶体和 PI3K-AKT 信号通路主要参与 RNF186 的细胞功能。此外，我们的研究首次证实 RNF186 可能作为一种癌基因，促进 UCEC 中的癌症增殖、迁移和侵袭。相反，RNF186 可能在 BRCA 进展中发挥抑制作用。这种功能取决于 RNF186 的连接酶活性。
本研究表明，RNF186 是 BRCA 和 UCEC 肿瘤进展的一个新的关键靶点。它表明 RNF186 可能与肿瘤免疫治疗有关，这可能为免疫治疗的预后提供有效的预测评估。
